Pharmaceutical News

RSS

Emerson Ecologics officially launches Emerson Quality Program

Emerson Ecologics, LLC announces the official launch of the Emerson Quality Program(SM) (EQP) on their website, www.emersonecologics.com/quality. This one-of-a-kind quality assurance program for the nutritional supplements industry will showcase the quality practices of the industry's leading manufacturers.

5 Feb 2010

Pazopanib drug slows the progression of RCC in patients by 54%

The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma (RCC), a form of kidney cancer, in patients by 54% percent, according to a new study published in the Journal of Clinical Oncology.

5 Feb 2010

New report finds low adult vaccination rates in U.S.

A new report, Adult Immunization: Shots to Save Lives, released today by the Trust for America's Health (TFAH), the Infectious Diseases Society of America (IDSA), and the Robert Wood Johnson Foundation (RWJF) found that more than 30 percent of adults ages 65 and older had not been immunized against pneumonia in 36 states as of 2008.

5 Feb 2010

Mylan first to file ANDA patent for Caduet Tablets

Mylan Inc. today confirmed that it was sued by Pfizer in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Amlodipine Besylate and Atorvastatin Calcium Tablets 2.5/10 mg, 2.5/20 mg, 2.5/40 mg, 5/10 mg, 5/20 mg, 5/40 mg, 5/80 mg, 10/10 mg, 10/20 mg, 10/40 and 10/80 mg.

5 Feb 2010

Report shows more Americans are buying prescription drugs to treat digestive conditions

The number of Americans buying prescription drugs to treat digestive conditions climbed over 50 percent, rising from 18.1 million to 29 million people between 1997 and 2007, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

5 Feb 2010

Elephantiasis and river blindness: MSU researcher receives $2M for reformulating flubendazole

In an effort to eliminate the tropical diseases elephantiasis and river blindness, a Michigan State University researcher has been awarded $2 million to reformulate an existing drug that could stop the debilitating diseases in their tracks.

5 Feb 2010

New class of compound could become effective antidepressant with minimal side effects

Chemists at Oregon State University have discovered and synthesized a new compound that in laboratory and animal tests appears to be similar to, but may have advantages over one of the most important antidepressant medications in the world.

5 Feb 2010

Early stage trial finds malaria vaccine effectively protected young children, study says

An experimental vaccine was found to effectively protect young children from malaria in Mali, Reuters reports. According to the news service, "The vaccine, which uses an immune system booster called an adjuvant from British drugmaker GlaxoSmithKline, targets the malaria parasite as it is actively infecting red blood cells and causing fever and illness" (Steenhuysen, 2/3).

5 Feb 2010

Children exposed to acetaminophen prenatally more likely to have asthma symptoms at age five

Children who were exposed to acetaminophen prenatally were more likely to have asthma symptoms at age five in a study of 300 African-American and Dominican Republic children living in New York City.

5 Feb 2010

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM).

5 Feb 2010

Lux Biosciences seeks US and European marketing approval for LUVENIQ

Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

5 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Lux Biosciences files NDA with FDA and MAA with EMA for approval of voclosporin

Isotechnika Pharma Inc. today announced that its partner, Lux Biosciences, Inc., has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Market Authorization Application (MAA) with the European Medicines Agency (EMA) for voclosporin, under the proposed brand name, LUVENIQ(TM).

4 Feb 2010

TenX Biopharma acquires exclusive global rights to zanolimumab from Genmab

TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S.

4 Feb 2010

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

Alkermes, Inc. today announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies.

4 Feb 2010

"Knowledge deficit" about methadone responsible for resulting deaths

In a unique and comprehensive literature review of poisoning deaths involving opioids from 1999 -- 2009, the deaths involving methadone were found to be disproportionately high. Methadone represented less than five percent of all opioid prescriptions but is responsible for a third of the deaths. After four years of investigation, the major underlying cause was found to be fundamental misunderstandings about the properties of the medicine -- a "knowledge deficit" -- especially when converting patients from other opioids.

4 Feb 2010

Expert available to discuss Lancet’s retraction of paper on autism study

Rae Sonnenmeier, clinical associate professor of communication sciences and disorders at the University of New Hampshire and staff member at UNH's Institute on Disability, is available to discuss the announcement yesterday (Feb. 2, 2010) by the medical journal The Lancet regarding the retraction of a paper that caused a 12-year international battle over the links between the three-in-one childhood vaccine MMR (measles, mumps, rubella) and autism.

4 Feb 2010

Phase Forward to participate in DIA Workshop and Clinical Trial Supply event

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, will participate in two industry events this month: The 13th Annual DIA Workshop in Japan for Clinical Data Management (Booths 4 and 5) and VIB Pharma’s 11th Annual Clinical Trial Supply (Booth 3).

4 Feb 2010

February issue of Chest releases latest medical news

Inhaled corticosteroids (ICS) are widely used for the treatment of chronic obstructive pulmonary disease (COPD). However, new research suggests that ICS may only provide a modest benefit in reducing exacerbations in patients with COPD.

4 Feb 2010

Discussion on IATA Chapter 17 compliance for temperature-sensitive products at 8th Cold Chain Summit

Pharma IQ, a division of IQPC, announces that Kevin O’Donnell Director & CTA of Tegrant Corporation and Chair of IATA’s Time & Temperature Task Force will discuss compliance with IATA’s revised Chapter 17 at the 8th Cold Chain Management and Temperature Control Summit.

From IQPC Ltd 4 Feb 2010

Pharmaceutical News

Emerson Ecologics officially launches Emerson Quality Program

Pazopanib drug slows the progression of RCC in patients by 54%

New report finds low adult vaccination rates in U.S.

Mylan first to file ANDA patent for Caduet Tablets

Report shows more Americans are buying prescription drugs to treat digestive conditions

Elephantiasis and river blindness: MSU researcher receives $2M for reformulating flubendazole

New class of compound could become effective antidepressant with minimal side effects

Early stage trial finds malaria vaccine effectively protected young children, study says

Children exposed to acetaminophen prenatally more likely to have asthma symptoms at age five

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Lux Biosciences seeks US and European marketing approval for LUVENIQ

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Lux Biosciences files NDA with FDA and MAA with EMA for approval of voclosporin

TenX Biopharma acquires exclusive global rights to zanolimumab from Genmab

Alkermes develops proprietary LinkeRx technology platform to create injectable antipsychotics

"Knowledge deficit" about methadone responsible for resulting deaths

Expert available to discuss Lancet’s retraction of paper on autism study

Phase Forward to participate in DIA Workshop and Clinical Trial Supply event

February issue of Chest releases latest medical news

Discussion on IATA Chapter 17 compliance for temperature-sensitive products at 8th Cold Chain Summit

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News